Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT06429384
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 240 participants
- Registry
-
NCT06429384
-
- Other papers using this trial's data
- Loberamisal injection for the treatment of acute ischaemic stroke: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06429384. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-04 (actual); primary completion 2023-11-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Y-3 Injection/Y-3 blank injection
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06429384- Content hash
3fbc843554807e6c729788b6200742374b2242f2de462046d664f2db91e143e4